SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative therapeutic approaches capable of addressing multiple metabolic pathways ...

MetaVia (MTVA) reported additional top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

Loss of skeletal muscle mass is a known risk factor for falls. Researchers from the University of Tsukuba conducted a 5-yr follow-up study on 471 patients with type 2 diabetes and found that ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

The oral glucagon-like peptide-1 receptor agonist (GLP-1RA ... a once daily glucose-dependent insulinotropic polypeptide (GIP ...

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...

Compounded semaglutide helps manage blood sugar and curb appetite for better diabetes control and weight loss. Learn how it ...